Pro­to­cols: BeiGene signs up Medi­va­tion’s Amy Pe­ter­son as its new CMO; Ac­ne drug de­vel­op­er files for $60M IPO

Now that Pfiz­er has bagged Medi­va­tion in its $14 bil­lion buy­out deal, the scram­ble for top tal­ent has be­gun. Chi­na’s BeiGene was one of the first to move, sign­ing Amy C. Pe­ter­son as its new chief med­ical of­fi­cer. Pe­ter­son had been the VP of clin­i­cal de­vel­op­ment at Medi­va­tion, and she’ll put the skills she learned ad­vanc­ing Medi­va­tion’s late-stage PARP in­hibitor ta­la­zoparib to use for BeiGene, which has its own PARP in the clin­ic now. Pe­ter­son will al­so work with BeiGene’s new PD-1 pro­gram. “BeiGene con­tin­ues to ex­pand its se­nior med­ical lead­er­ship in re­sponse to emerg­ing glob­al de­vel­op­ment op­por­tu­ni­ties, par­tic­u­lar­ly in im­muno-on­col­o­gy,” not­ed BeiGene CEO John Oyler. BeiGene al­so has a fa­cil­i­ty in Waltham, MA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.